Llibre Alba, Duffy Darragh
Immunobiology of Dendritic Cells, Institut Pasteur, Paris, France; INSERM U1223, Paris, France.
Immunobiology of Dendritic Cells, Institut Pasteur, Paris, France; INSERM U1223, Paris, France.
Comp Immunol Microbiol Infect Dis. 2018 Aug;59:57-62. doi: 10.1016/j.cimid.2018.09.008. Epub 2018 Sep 24.
Biomarkers are increasingly utilised in biological research and clinical practice for diagnosis of disease, monitoring of therapeutic prognosis, or as end points in clinical studies. Cytokines are small molecules that orchestrate immune responses and as such have great potential as biomarkers for both human and veterinary fields. Given the ease of sampling in the blood, and their high prevalence in clinical applications we will focus on protein detection as an area for biomarker discovery. This is facilitated by new technological developments such as digital ELISA that have led to significant increases in sensitivity. Two highly relevant examples include type I interferons, namely IFNα, that is now directly quantifiable by digital ELISA from biological samples. The application of this approach to the study of the unique bat interferon response may reveal novel findings with applications in both human and veterinary research. As a second example we will describe the use of CXCL10 as a disease biomarker in Tuberculosis, highlighting findings from human and mouse studies that should be considered in veterinary research. In summary, we describe how cytokines may be applied as novel biomarkers and illustrate two key examples where human and veterinary research may complement each other in line with the One Health objectives.
生物标志物在生物学研究和临床实践中越来越多地用于疾病诊断、治疗预后监测或作为临床研究的终点。细胞因子是协调免疫反应的小分子,因此作为人类和兽医领域的生物标志物具有巨大潜力。鉴于血液采样的便利性以及它们在临床应用中的高普遍性,我们将专注于蛋白质检测作为生物标志物发现的一个领域。数字酶联免疫吸附测定法(digital ELISA)等新技术的发展促进了这一点,这些技术显著提高了灵敏度。两个高度相关的例子包括I型干扰素,即IFNα,现在可以通过数字酶联免疫吸附测定法直接从生物样品中进行定量。将这种方法应用于独特的蝙蝠干扰素反应研究可能会揭示在人类和兽医研究中都有应用的新发现。作为第二个例子,我们将描述CXCL10作为结核病疾病生物标志物的用途,强调人类和小鼠研究的结果,这些结果在兽医研究中应予以考虑。总之,我们描述了细胞因子如何作为新型生物标志物应用,并举例说明了两个关键例子,即人类和兽医研究如何根据“同一健康”目标相互补充。